CAR T cell therapy for multiple myeloma: where are we now and where are we headed?

Arnab GhoshHematology/Oncology/BMT Fellowship Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA;

Sham MailankodyMyeloma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA;

Sergio A. GiraltAdult BMT Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA; ;Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA;

C. Ola LandgrenMyeloma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA;

http://orcid.org/0000-0001-6485-4839

Eric L. SmithMyeloma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; ;Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Correspondence[email protected]

Renier J. BrentjensCellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA; ;Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA

CAR T cell therapy for multiple myeloma: where are we now and where are we headed?

ICMJE Form for Disclosure of Potential Conflicts of Interest

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

CAR T cell therapy for multiple myeloma: where are we now and where are we headed?

ICMJE Form for Disclosure of Potential Conflicts of Interest

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date